- Home
- / Samsung Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Samsung Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩1.6 K
2024-10-29
Market Capitalization
₩148.9 B
2024-10-29
Revenue
₩52 B
FY, 2023
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 46.5B | 44.6B | 48.3B | 54.9B | 51.8B | 52.0B |
| Cost of goods sold | 37.9B | 36.4B | 28.1B | 50.0B | 28.3B | 27.2B |
| Gross profit | 13.4B | 26.5B | 22.5B | 6.2B | 28.7B | 26.1B |
| Gross profit margin, % | 28.9% | 59.5% | 46.7% | 11.3% | 55.4% | 50.2% |
| Operating expense total | 13.4B | 10.4B | 26.0B | 33.3B | 40.8B | 40.8B |
| Depreciation and amortization | 7.8B | 8.4B | 5.4B | 7.6B | 10.3B | |
| EBITDA | 56.4M | 15.7B | (20.9B) | (27.2B) | (12.0B) | (13.9B) |
| EBITDA margin, % | 0.1% | 35.2% | -43.2% | -49.6% | -23.2% | -26.7% |
| EBIT | (1.9B) | 4.4B | (29.4B) | (38.9B) | (26.1B) | (24.3B) |
| EBIT margin, % | -4.1% | 9.9% | -61.0% | -70.8% | -50.4% | -46.9% |
| Interest income | 1.2B | 636.4M | 173.9M | 549.4M | 726.5M | 806.7M |
| Interest expense | 1.4B | 707.6M | 2.1B | 506.9M | 111.1M | 73.4M |
| Pre tax profit | (2.0B) | 7.1B | (39.9B) | (40.3B) | (25.1B) | (23.7B) |
| Income tax expense | 59.6M | 201.7M | 1.1B | |||
| Net Income | (2.1B) | 6.9B | (39.9B) | (40.3B) | (25.1B) | (24.8B) |